A New Treatment for Chronic Obstructive Pulmonary Disease: Ensifentrine Moves Closer
Author:
Affiliation:
1. Manchester University National Health Service Foundation TrustUniversity of ManchesterManchester, United Kingdom
Publisher
American Thoracic Society
Subject
Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine
Link
https://www.atsjournals.org/doi/pdf/10.1164/rccm.202307-1164ED
Reference14 articles.
1. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
2. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
3. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review
4. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
5. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease;Trends in Pharmacological Sciences;2024-09
2. Using a Portable Ventilatory Airway Screening (PVAS) Device to Evaluate the Difference Between Upper Airway Breathing Pressure and Respiratory Flow in Skeletal Class I and Class II Growing Individuals With Retrognathic Mandible;Cureus;2024-06-22
3. The future drug treatment of COPD;COPD in the 21st Century;2024-03-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3